Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 216 participants.

Also called NCT03785405

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 216 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03785405
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Austria, Bulgaria, Canada, Croatia, Czechia, Finland, France, Germany, Hungary, India, Israel, Italy, Japan, Lebanon, Poland, Portugal, Russia, Singapore, South Africa, South Korea, Spain, Switzerland, Taiwan, Thailand, Türkiye (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03785405. Allocation not applicable; no masking; primary purpose treatment. Start 2019-05-02 (actual); primary completion 2023-12-29 (actual). Results posted on 2024-07-16.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF
Condition
Heart Failure
Intervention (Drug)
sacubitril/valsartan
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct03785405
Content hash
84b3b47fe48b7d4b666c777dde4648f348359e9c5695a44cc022f98dfb24c48f